ThermoGenesis Holdings (NSDQ:THMO) announced today that it filed patent applications for its point-of-care COVID-19 antibody detection device. Rancho Cordova, Calif.-based ThermoGenesis’ device is designed to improve the speed and accuracy of lateral flow immunoassays (LFIA) in detecting COVID-19 IgM and IgG antibodies from a single drop of blood. In a news release, ThermoGenesis chief technology […]
ThermoGenesis Corp.
Greatbatch proposes to mostly exit Switzerland for Indiana, Mexico | Wall Street Beat
Greatbatch (NYSE:GB) said it wants to largely shutter a pair of plants in Switzerland and relocate their operations to Ft. Wayne, Ind., and Tijuana, Mexico.
Boston Scientific touts CMS reimbursement nod for asthma treatment | Regulatory Roundup
Boston Scientific Corp.’s (NYSE:BSX) Alair asthma management system won reimbursement from the Centers for Medicare & Medicaid Services, effective at the start of this year.
The Alair system delivers precise thermal energy lung to tissue via bronchoscope to reduce excessively smooth muscle, decreasing the airway’s ability to constrict.
Geron’s exit from stem cell business means opportunity for InVivo, others
Covidien lands 510(k) clearance and CE Mark approval for its next-gen Parietex mesh | Regulatory Roundup
Covidien plc (NYSE:COV) announced a double-dose of regulatory wins for its Parietex Optimized Composite (PCOx) mesh, which received both 510(k) clearance from the U.S. Food & Drug Administration and CE Mark approval for the European Union.
Covidien launched PCOx during the recent European Hernia Society meeting in Ghent, Belgium, and the product will be commercially available in the U.S. and Europe starting in June.
PerkinElmer Q1 profits inch downward despite 14 percent sales increase | Earnings roundup
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
FDA approves spine sealant from Covidien | Regulatory roundup
Here’s a roundup of companies announcing clearances and approvals from the FDA and foreign regulatory agencies. Check out MassDevice’s compilation of the latest regulatory news for additional clearances and approvals.
BG Medicine inks pact with Boston Scientific for heart failure research | Deals roundup
BG Medicine Inc. (NSDQ:BGMD) signed yet another deal involving its galectin-3 heart failure test, this time with Boston Scientific Corp. (NYSE:BSX)
The Natick, Mass.-based cardiac device giant is studying whether Waltham, Mass.-based BG’s diagnostic can identify patients in need of cardiac-resynchronization therapy using patient data from its Madit-CRT clinical trial.
BD inks licensing deal with University College London | Distribution roundup
Here’s a roundup of companies announcing new distribution deals.
LabCorp earnings dip, sales rise 11 percent | Earnings roundup
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Troubled ThermoGenesis nears the break-even point
ThermoGenesis Corp. (NSDQ:KOOLD) almost broke even during the fourth quarter after posting a 78 percent revenue spike.
The Rancho Cordova, Calif.-based stem-cell-storage device maker posted a net loss of $171,000, or 1 cent per diluted share, on sales of $7.2 million during the three months ended June 30. That compares with net losses of $3.1 million, or 22 cents per diluted share, on sales of $4.0 million during the same period last year.
